Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is testing a medicine called magrolimab with other cancer treatments to see if it is safe and works well for people with multiple myeloma who have not been helped by other treatments. The study will test different combinations of medicines to find out the best dose and how well they work together.
This study is testing a medicine called magrolimab with other cancer treatments to see if it is safe and works well for people with multiple myeloma who have not been helped by other treatments. The study will test different combinations of medicines to find out the best dose and how well they work together.
*Third Opinion AI Generated Synopsis
Trial Summary
The primary objective of this study for the Safety Run-in Cohorts is to evaluate the safety and tolerability of magrolimab in combination with other anticancer therapies and to determine the recommended Phase 2 dose (RP2D) of magrolimab in participants with relapsed/refractory multiple myeloma (MM) for the following combinations: magrolimab + daratumumab, magrolimab + pomalidomide + dexamethasone, and magrolimab + bortezomib + dexamethasone. The primary objective of this study for the Dose Expansion Cohorts is to evaluate the efficacy of magrolimab in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma as determined by objective response rate (ORR).
The primary objective of this study for the Safety Run-in Cohorts is to evaluate the safety and tolerability of magrolimab in combination with other anticancer therapies and to determine the recommended Phase 2 dose (RP2D) of magrolimab in participants with relapsed/refractory multiple myeloma (MM) for the following combinations: magrolimab + daratumumab, magrolimab + pomalidomide + dexamethasone, and magrolimab + bortezomib + dexamethasone. The primary objective of this study for the Dose Expansion Cohorts is to evaluate the efficacy of magrolimab in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma as determined by objective response rate (ORR).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.